New oral agents for treating dyslipidemia

Current Opinion in Lipidology

Volumn 27, Issue 6, 2016, Pages 579-584

  Gryn, Steven E ^a   Hegele, Robert A ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Bempedoic acid; Gemcabene; Hypolipidemic agents; Peroxisome proliferator activated receptors; Pradigastat; V 3 fatty acids

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ANTILIPEMIC AGENT; BEMPEDOIC ACID; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIACYLGLYCEROL ACYLTRANSFERASE INHIBITOR; GEMCABENE; OMEGA 3 FATTY ACID; PEMAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATOR; PRADIGASTAT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

DYSLIPIDEMIA; HUMAN; PRIORITY JOURNAL; REVIEW; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS;

EID: 84988683833     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000354     Document Type: Review

References (36)

1. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374:2021-2031.
2. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J 2015; 36:1012-1022.
3. Hegele RA, Gidding SS, Ginsberg HN, et al. Nonstatin low-density lipoprotein- lowering therapy and cardiovascular risk reduction-statement from ATVB council. Arterioscler Thromb Vasc Biol 2015; 35:2269-2280.
4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387-2397.
5. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 2016; 315:1580-1590.
6. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
7. Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition is not yet dead pro. Arterioscler Thromb Vasc Biol 2016; 36:439-441.
8. Tardif JC, Rheaume E, Lemieux Perreault LP, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015; 8:372-382.
9. Millar JS, Reyes-Soffer G, Jumes P, et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest 2015; 125:2510-2522.
10. Reyes-Soffer G, Millar JS, Ngai C, et al. Cholesteryl ester transfer protein inhibition with anacetrapib decreases fractional clearance rates of highdensity lipoprotein apolipoprotein A-I and plasma cholesteryl ester transfer protein. Arterioscler Thromb Vasc Biol 2016; 36:994-1002.
11. Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol 2014; 25:309-315.
12. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 2013; 54:134-151.
13. Fullerton MD. AMP-activated protein kinase and its multifaceted regulation of hepatic metabolism. Curr Opin Lipidol 2016; 27:172-180.
14. Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2014; 34:676-683.
15. Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol 2015; 9:295-304.
16. Thompson PD, MacDougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol 2016; 10:556-567.
17. Burke AC, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Newton RS, Huff MW. Bempedoic acid lowers low density lipoprotein cholesterol and attenuates aortic atherosclerosis in LDL receptor deficient (LDLR +/- and LDLR -/-) Yucatan miniature pigs. In: Arteriosclerosis Thrombosis and Vascular Biology Scientific Sessions. Nashville, TN: 2016. p. 39.
18. Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J 2005; 7:E513-E522.
19. Bays HE, McKenney JM, Dujovne CA, et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of highdensity lipoprotein cholesterol. Am J Cardiol 2003; 92:538-543.
20. Liu ZM, Hu M, Chan P, Tomlinson B. Early investigational drugs targeting PPAR-a for the treatment of metabolic disease. Expert Opin Investig Drugs 2015; 24:611-621.
21. Gryn SE, Hegele RA. Novel therapeutics in hypertriglyceridemia. Curr Opin Lipidol 2015; 26:484-491.
22. Khera AV, Millar JS, Ruotolo G, et al. Potent peroxisome proliferator-activated receptor-a agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J 2015; 36:3020-3022.
23. Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARa modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis 2016; 249:36-43.
24. Erdmann E, Califf R, Gerstein HC, et al. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 diabetes mellitus or prediabetes. Am Heart J 2015; 170: 117-122.
25. Stirban AO, Andjelkovic M, Heise T, et al. Aleglitazar, a dual peroxisome proliferator-activated receptor- a/g agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial. Diabetes Obes Metab 2016; 18:711-715.
26. Henry RR, Buse JB, WuH, et al. Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. Diabetes Obes Metab 2015; 17:560-565.
27. Denison H, Nilsson C, Lofgren L, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab 2014; 16:334-343.
28. Meyers CD, Amer A, Majumdar T, Chen J. Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects. J Clin Pharmacol 2015; 55:1031-1041.
29. Meyers CD, Tremblay K, Amer A, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis 2015; 14:8.
30. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110:984-992.
31. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108:682-690.
32. Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013; 13:37-46.
33. Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity c-reactive protein and lipid parameters in patients with metabolic syndrome. Metab Syndr Relat Disord 2015; 13:239-247.
34. Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol 2016; 10:635-645.
35. Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa for lowering very high triglyceridEs (EVOLVE) trial. J Clin Lipidol 2014; 8: 94-106.
36. Roth EM. v-3 carboxylic acids for hypertriglyceridemia. Expert Opin Pharmacother 2015; 16:123-133.